Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Children | Hospitals | Immunotherapy | Neuroblastoma | Neurology | Research | Spironolactone